RT Journal Article
SR Electronic
T1 Cerebral Venous Sinus Thrombosis With Severe Thrombocytopenia: A Fatal Adverse Event Following Johnson & Johnson COVID-19 Vaccination
JF Neurology: Clinical Practice
FD Lippincott Williams & Wilkins
SP 10.1212/CPJ.0000000000001137
DO 10.1212/CPJ.0000000000001137
A1 Ali, Murtaza
A1 Goshgarian, Christopher
A1 Jameson, Andrew
YR 2021
UL http://cp.neurology.org/content/early/2021/10/07/CPJ.0000000000001137.abstract
AB Approximately 7.98 million doses of the Johnson and Johnson adenovirus vector SARS-CoV-2 vaccine (J&J vaccine) have been administered since EUA authorization by the FDA on February 27, 20211, 2. On April 13th, the CDC/FDA recommended a pause in administration after 6 cases of cerebral venous sinus thrombosis (CVST) with thrombocytopenia were identified through the vaccine adverse event reporting system in women aged 18-48. To date, 15 cases of thrombosis with thrombocytopenia syndrome (TTS) have been reported following vaccination with J&J, with three reported fatalities2. Here we report one of those fatalities in a 35-year-old woman who developed CVST with thrombocytopenia following vaccination with the J&J vaccine.